Fighting cancer with the immune system

June 11, 2012

The human immune system has a natural ability to identify and attack tumor cells. Natural killer (NK) cells are innate immune cells that are particularly effective at killing tumor cells due to their ability to secrete cytotoxic enzymes. However, mutations have allowed many types of tumors to develop a resistance to NK-mediated killing through ill-defined mechanisms.

Dr. Jerome Ritz and colleagues at the Dana-Farber Cancer Institute in Boston sought to pinpoint some of these mechanisms using a library of short hairpin RNAs (shRNA), a type of RNA that binds complementary in the cell and prevents their transcription into proteins.

His group used a multiple myeloma cell line to screen for genes whose reduced expression increased susceptibility of the cancer cells to NK-mediated death. They identified dozens of genes that, when shut down by shRNA, allowed increased tumor cell killing by NK cells. The strongest effect was induced by silencing proteins called JAK1 and JAK2, kinases important for integrating signals from many membrane . In addition to targeting these kinases by shRNA, the research team showed that pharmacological inhibition of JAK1 and 2 also increased tumor cell killing. Many kinase inhibitors being used or tested today identified in this screen.

The researchers suggest that targeting the JAK1 and 2 pathways in particular may aid in eradicating tumors that have developed mechanisms to escape NK cell killing.

Explore further: Immune cells link pregnancy and tumor spread

More information: Tyrosine kinase pathways modulate tumor susceptibility to natural killer cells, Journal of Clinical Investigation, doi:10.1172/JCI58457 .

Related Stories

Immune cells link pregnancy and tumor spread

June 6, 2011

Individuals with cancer often do not die as a result of their initial tumor but as a result of tumors at distant sites that are derived from the initial tumor. Pregnancy is a condition that seems to be permissive for tumor ...

Scientists discover important cancer defence switch

December 14, 2011

(Medical Xpress) -- A multi-disciplinary team of researchers at King’s College London have captured the first live images of a key molecular switch in the body’s natural defence system against tumour cells.

Enhancing the effectiveness of a breast cancer treatment

February 13, 2012

Breast cancers expressing the protein HER2 have a particularly poor prognosis. Treatment with trastuzumab (Herceptin) benefits some patients with HER2-positive breast cancer, but it is not as effective as had been hoped. ...

Recommended for you

Forecasting the path of breast cancer in a patient

November 23, 2015

USC researchers have developed a mathematical model to forecast metastatic breast cancer survival rates using techniques usually reserved for weather prediction, financial forecasting and surfing the Web.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.